Neumann Lab is striving to Maximize the outcome of erythropoietin treatment in cancer related anemia.
Erythropoietin (EPO) is frequently used in clinical practice for treating anemia of various etiologies, including these that accompany certain types of neoplasia.
In addition to the clear effect of EPO on hematocrit levels, we have noted improved immunological functions and prolonged survival in multiple myeloma (MM) mouse models and MM patients, linked to EPO administration. However, EPO treatment in mice has been shown to induce a significant bone loss. Our studies are thus directed towards deciphering the interplay between the immune and skeletal systems and the role of EPO in this process. Our findings will suggest methods to realize the therapeutic potential of EPO by optimizing the erythroid-stimulating effects while attenuating the risk for bone loss and associated fractures.
Prof. Drorit Neumann PhD
Sackler Faculty of Medicine